

Pacira Pharmaceuticals, Inc.
 Form 4
 January 02, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
LONGENECKER JOHN P PHD

(Last) (First) (Middle)

**C/O PACIRA
 PHARMACEUTICALS,
 INC., 10450 SCIENCE CENTER
 DRIVE**

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Pacira Pharmaceuticals, Inc. [PCRX]

3. Date of Earliest Transaction
 (Month/Day/Year)

12/30/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V | Amount or Price | | |
| Common Stock | 12/30/2013 | | M | | 581 A \$ 1.61 | 581 | D |
| Common Stock | 12/30/2013 | | M | | 1,345 A \$ 1.61 | 1,926 | D |
| Common Stock | 12/30/2013 | | M | | 574 A \$ 1.61 | 2,500 | D |
| Common Stock | 12/30/2013 | | S ⁽¹⁾ | | 2,500 D \$ 55.55 | 0 | D |

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (right to buy) | \$ 1.61 | 12/30/2013 | | M | 581 | ⁽²⁾ 09/02/2020 | Common Stock | 581 |
| Stock Option (right to buy) | \$ 1.61 | 12/30/2013 | | M | 1,345 | ⁽³⁾ 09/02/2020 | Common Stock | 1,345 |
| Stock Option (right to buy) | \$ 1.61 | 12/30/2013 | | M | 574 | ⁽⁴⁾ 09/02/2020 | Common Stock | 574 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| LONGENECKER JOHN P PHD C/O PACIRA PHARMACEUTICALS, INC. 10450 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 | X | | | |

Signatures

/s/ James Scibetta,
attorney-in-fact

01/02/2014

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.

(3) The option vested as to 50% of the options upon the first anniversary of the Issuer's initial public offering and as to the remaining 50% of the options upon the second anniversary of the Issuer's initial public offering. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.

(4) The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.